Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short term Debt: 2010-2025

Historic Short term Debt for Cytokinetics (CYTK) over the last 6 years, with Sep 2025 value amounting to $17.3 million.

  • Cytokinetics' Short term Debt rose 38.24% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 38.24%. This contributed to the annual value of $11.5 million for FY2024, which is 14.29% up from last year.
  • Per Cytokinetics' latest filing, its Short term Debt stood at $17.3 million for Q3 2025, which was down 1.82% from $17.6 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Short term Debt registered a high of $17.6 million during Q2 2025, and its lowest value of $958,000 during Q4 2022.
  • Moreover, its 3-year median value for Short term Debt was $12.7 million (2024), whereas its average is $13.3 million.
  • Data for Cytokinetics' Short term Debt shows a peak YoY spiked of 952.19% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Cytokinetics' Short term Debt stood at $16.9 million in 2021, then reached $958,000 in 2022, then soared by 952.19% to $10.1 million in 2023, then grew by 14.29% to $11.5 million in 2024, then soared by 38.24% to $17.3 million in 2025.
  • Its Short term Debt stands at $17.3 million for Q3 2025, versus $17.6 million for Q2 2025 and $13.0 million for Q1 2025.